Press release
Chemotherapy Induced Anemia Pipeline Overview 2024: FDA Approvals and Key Developments, Therapies, Mechanism of Action, Route of Administration, and Developments | Fibrogen, SBI Pharmaceuticals, Zydus Cadila, FibroGen, Johnson & Johnson, Affymax, Chugai P
"Chemotherapy Induced Anemia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chemotherapy Induced Anemia Market.
The Chemotherapy Induced Anemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chemotherapy Induced Anemia Pipeline Report: https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Chemotherapy Induced Anemia treatment therapies with a considerable amount of success over the years.
• Chemotherapy Induced Anemia companies working in the treatment market are Fibrogen, SBI Pharmaceuticals, Zydus Cadila, FibroGen, Johnson & Johnson, Affymax, Chugai Pharmaceutical, Hoffmann-La Roche, Amgen, Astellas Pharma, and others, are developing therapies for the Chemotherapy Induced Anemia treatment
• Emerging Chemotherapy Induced Anemia therapies in the different phases of clinical trials are- Roxadustat, Desidustat, SEPO®, Epoetin alfa, peginesatide, epoetin beta, r-HuEPO, Aranesp, Gilteritinib, and others are expected to have a significant impact on the Chemotherapy Induced Anemia market in the coming years.
• In November 2024, FibroGen anticipates an approval decision for roxadustat in the treatment of chemotherapy-induced anemia (CIA) in China by early 2025. If approved, FibroGen is set to receive a $10 million milestone payment from AstraZeneca.
Chemotherapy Induced Anemia Overview
Chemotherapy Induced Anemia (CIA) is a condition where a patient undergoing chemotherapy develops a reduction in red blood cells or hemoglobin levels, leading to fatigue, weakness, and shortness of breath. Chemotherapy can damage the bone marrow, impairing its ability to produce red blood cells. This condition is common in cancer patients, as chemotherapy targets rapidly dividing cells, including healthy ones like those in the bone marrow. CIA can be managed through treatments like erythropoiesis-stimulating agents, blood transfusions, and iron supplementation, depending on the severity.
Get a Free Sample PDF Report to know more about Chemotherapy Induced Anemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Chemotherapy Induced Anemia Drugs Under Different Phases of Clinical Development Include:
• Roxadustat :
• SPP-003 : SBI Pharmaceuticals
• Roxadustat: Fibrogen
• Desidustat: Zydus Cadila
• SEPO®: FibroGen
• Epoetin alfa: Johnson & Johnson
• peginesatide: Affymax
• epoetin beta: Chugai Pharmaceutical
• r-HuEPO: Hoffmann-La Roche
• Aranesp: Amgen
• Gilteritinib: Astellas Pharma
Chemotherapy Induced Anemia Route of Administration
Chemotherapy Induced Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Chemotherapy Induced Anemia Molecule Type
Chemotherapy Induced Anemia Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Chemotherapy Induced Anemia Pipeline Therapeutics Assessment
• Chemotherapy Induced Anemia Assessment by Product Type
• Chemotherapy Induced Anemia By Stage and Product Type
• Chemotherapy Induced Anemia Assessment by Route of Administration
• Chemotherapy Induced Anemia By Stage and Route of Administration
• Chemotherapy Induced Anemia Assessment by Molecule Type
• Chemotherapy Induced Anemia by Stage and Molecule Type
DelveInsight's Chemotherapy Induced Anemia Report covers around 3+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Chemotherapy Induced Anemia product details are provided in the report. Download the Chemotherapy Induced Anemia pipeline report to learn more about the emerging Chemotherapy Induced Anemia therapies at:
https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Chemotherapy Induced Anemia Therapeutics Market include:
Key companies developing therapies for Chemotherapy Induced Anemia are - Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Pfizer Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, FibroGen, Inc., Astella Pharma, and others.
Chemotherapy Induced Anemia Pipeline Analysis:
The Chemotherapy Induced Anemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Anemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Anemia Treatment.
• Chemotherapy Induced Anemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chemotherapy Induced Anemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Anemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Chemotherapy Induced Anemia drugs and therapies-
https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Chemotherapy Induced Anemia Pipeline Market Drivers
• Growing Cancer Incidence, Advancements in Targeted Therapies, Unmet Medical Need, Increasing Awareness, Government and Private Investments, Improved Diagnostic Technologies, are some of the important factors that are fueling the Chemotherapy Induced Anemia Market.
Chemotherapy Induced Anemia Pipeline Market Barriers
• However, High Treatment Costs, Side Effects of Current Treatments, Regulatory Hurdles, Limited Efficacy of Available Drugs, Lack of Standardized Treatment Protocols, Resistance to Novel Treatments, and other factors are creating obstacles in the Chemotherapy Induced Anemia Market growth.
Scope of Chemotherapy Induced Anemia Pipeline Drug Insight
• Coverage: Global
• Key Chemotherapy Induced Anemia Companies: Fibrogen, SBI Pharmaceuticals, Zydus Cadila, FibroGen, Johnson & Johnson, Affymax, Chugai Pharmaceutical, Hoffmann-La Roche, Amgen, Astellas Pharma, and others
• Key Chemotherapy Induced Anemia Therapies: Roxadustat, Desidustat, SEPO®, Epoetin alfa, peginesatide, epoetin beta, r-HuEPO, Aranesp, Gilteritinib, and others
• Chemotherapy Induced Anemia Therapeutic Assessment: Chemotherapy Induced Anemia current marketed and Chemotherapy Induced Anemia emerging therapies
• Chemotherapy Induced Anemia Market Dynamics: Chemotherapy Induced Anemia market drivers and Chemotherapy Induced Anemia market barriers
Request for Sample PDF Report for Chemotherapy Induced Anemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Chemotherapy Induced Anemia Report Introduction
2. Chemotherapy Induced Anemia Executive Summary
3. Chemotherapy Induced Anemia Overview
4. Chemotherapy Induced Anemia- Analytical Perspective In-depth Commercial Assessment
5. Chemotherapy Induced Anemia Pipeline Therapeutics
6. Chemotherapy Induced Anemia Late Stage Products (Phase II/III)
7. Chemotherapy Induced Anemia Mid Stage Products (Phase II)
8. Chemotherapy Induced Anemia Early Stage Products (Phase I)
9. Chemotherapy Induced Anemia Preclinical Stage Products
10. Chemotherapy Induced Anemia Therapeutics Assessment
11. Chemotherapy Induced Anemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chemotherapy Induced Anemia Key Companies
14. Chemotherapy Induced Anemia Key Products
15. Chemotherapy Induced Anemia Unmet Needs
16 . Chemotherapy Induced Anemia Market Drivers and Barriers
17. Chemotherapy Induced Anemia Future Perspectives and Conclusion
18. Chemotherapy Induced Anemia Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Chemotherapy Induced Anemia Market https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Chemotherapy Induced Anemia Epidemiology https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chemotherapy Induced Anemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight
• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Interspinous Spacers Market: https://www.delveinsight.com/report-store/interspinous-spacers-market
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chemotherapy Induced Anemia Pipeline Overview 2024: FDA Approvals and Key Developments, Therapies, Mechanism of Action, Route of Administration, and Developments | Fibrogen, SBI Pharmaceuticals, Zydus Cadila, FibroGen, Johnson & Johnson, Affymax, Chugai P here
News-ID: 3789369 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Chemotherapy
Chemotherapy Devices Market - Innovation for Life: Chemotherapy Devices Driving …
Newark, New Castle, USA: The "Chemotherapy Devices Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Chemotherapy Devices Market: https://www.growthplusreports.com/report/chemotherapy-devices-market/8623
This latest report researches the industry structure, sales, revenue,…
Chemotherapy Devices Market 2022 Will Boom With Advanced Chemotherapy Technologi …
New Research Study ""Chemotherapy Devices Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities), Size, Share and Outlook"" has been added to Coherent Market insight
The most recent Global Chemotherapy Devices Market report includes a high-level overview of the industry as well as in-depth analysis of key areas. The overview presented highlights the definition of products and services, as well as their associated applications, at the…
Cancer, chemotherapy and its treatment
Chemotherapy is one of the most commonly used cancer therapies. It employs the use of certain medications to destroy cancer cells or prevent them from spreading to other parts of the body. Chemotherapy may be prescribed alone or in combination with surgery or radiation therapy. Along with chemotherapy, you may also take newer types of cancer-fighting medications.
Chemotherapy can be taken as pills or as injections. You may visit a clinic…
Chemotherapy induced Nausea and Vomiting (CINV) TreatmentS Market Driven by Risi …
According to WHO cancer is one of the most leading causes for death with around 8 million deaths and 14 million new patients in 2012. Chemotherapy, which is received by approximately four million cancer patients each year, is among the most commonly used treatment to fight cancer. However, this mode of treatment has many side effects, an estimate of around 70% - 80% of the patients receiving chemotherapy treatment experience…
Nano Chemotherapy Market Nano Chemotherapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Nano Chemotherapeutics Mediations andndash; Solicitation to Nanomedicine
1.1 Overview
1.2 Nano Chemotherapeutics with Pharmaceutical Potential
Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations
2.1 Limitations of Conventional Chemotherapy
2.2 Nanotechnology in Cancer Targeting
2.2.1 Active Targeting
2.2.2 Passive Targeting
2.2.3 pH Dependent Drug Delivery Through Nanoparticles
Role…
Nano Chemotherapy Is Emerging As An Important Anti-Cancer Modality By Supplement …
“Global Nano Chemotherapy Market and Clinical Trials Outlook 2022” report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Download Report:…
